Welcome to our dedicated page for Perimeter Medical Imaging Ai news (Ticker: PYNKF), a resource for investors and traders seeking the latest updates and insights on Perimeter Medical Imaging Ai stock.
Perimeter Medical Imaging AI develops real-time optical coherence tomography imaging systems and artificial-intelligence tools for cancer surgery. The company’s Claire OCT+AI device has FDA premarket approval for intraoperative breast cancer margin assessment, while its S-Series OCT platform provides ultra-high-resolution cross-sectional visualization of excised tissue.
Company news commonly covers FDA regulatory milestones, product demonstrations, commercialization activity, clinical and technology updates, operating and financial results, investor conference presentations, and capital-structure actions such as private placements, warrants, and stock-option matters.
Perimeter Medical Imaging AI (OTCQX: PYNKF) reported preliminary results for Q2 2026, highlighting continued commercial progress and cost improvements. Revenue was approximately $503,000, entirely recurring from S-Series consumables, leases, maintenance services and ESP warranties, essentially flat versus $506,000 in Q1-2025 and up 31% from about $385,000 in Q1-2026.
Operating expenses for the quarter were approximately $3.1 million, down 28% from $4.3 million a year earlier. Net loss improved to about $2.6 million, or $0.02 per share, compared with roughly $3.9 million, or $0.04 per share, in Q2 2025. Cash used in operating activities for the six months ended June 30, 2026 was approximately $5.1 million, a 23% decrease from the comparable 2025 period, and cash at June 30, 2026 was about $6.4 million.
Commercially, Perimeter transitioned from its legacy S-Series OCT to the FDA PMA-approved Claire OCT+AI, securing the first two Claire placements as S-Series replacements at two top-tier hospitals and the first U.S. health-system deployment at Intermountain Health. The company also completed an equity “Life Offering” of 21,489,000 units at $0.35 per unit and issued an aggregate C$6,040,000 of 3.59% convertible debentures.
Perimeter Medical Imaging AI (OTCQX:PYNKF) will release its second quarter 2026 financial and operating results after market close on Thursday, August 20, 2026, followed by a webcast and conference call at 5:00 p.m. Eastern Time, accessible via North American and international dial-in numbers and the company website.
According to Perimeter, it also closed a final tranche of its May 2026 Life Offering on May 8, issuing an additional 1,955,500 units at C$0.35 for gross proceeds of C$684,425, bringing the total offering to 21,489,000 units (C$7,521,150), and paying about C$47,910 in extra cash commission plus 136,885 additional Broker Warrants.
Perimeter Medical Imaging AI (OTCQX:PYNKF) announced that Intermountain Health has become the first U.S. health system to commercially deploy Perimeter's Claire OCT System™, described as the only FDA-approved, AI-enabled imaging device for intraoperative margin assessment during breast-conserving breast cancer surgery.
Claire uses optical coherence tomography to provide real-time, cellular-level visualization of excised tissue, while integrated AI highlights areas of concern to support surgeons' decisions in the operating room. According to Perimeter, the system is now in clinical use at Intermountain’s LDS Hospital and American Fork Hospital under a systemwide agreement, marking Claire’s transition from clinical trial use into routine clinical practice.
Perimeter Medical Imaging AI (OTCQX:PYNKF, TSXV:PINK) announced that CEO Adrian Mendes will present a company update at the Planet MicroCap Showcase in Las Vegas on Wednesday, June 17, 2026, at 12:00 p.m. PDT (3:00 p.m. EDT).
A live and archived webcast of the presentation will be available on Perimeter's website, and investors can register for the event and request 1x1 meetings with management.
Perimeter (OTCQX:PYNKF) was selected for the INOVAIT Pilot Fund to advance AI for its FDA-approved intraoperative breast cancer imaging platform Claire™.
The project, partnered with the University of Toronto, may receive up to about $148,000 from INOVAIT plus a $100,000 Mitacs award.
Perimeter (OTCQX:PYNKF) reported Q1 2026 revenue of approximately $385,000, all from recurring sources, versus $550,000 in Q1 2025, which included $230,000 of one-time capital equipment sales.
Operating expenses fell 30% to $3.2 million, net loss improved 31% to $3.0 million, and cash used in operations declined 41% to $2.2 million. Perimeter received FDA PMA approval for its AI-enabled Claire OCT device, secured its first two commercial placements, cancelled 14.5 million warrants, repriced employee options, and raised roughly $7.5 million in gross proceeds through debentures and a unit offering, with up to $3.0 million more debentures expected.
Perimeter Medical Imaging AI (OTCQX:PYNKF) will release its first quarter 2026 financial and operating results after market close on Thursday, May 28, 2026. Management will host a webcast and conference call at 5:00 p.m. Eastern Time to discuss results and provide a corporate update.
The call will be accessible via dial-in numbers for North America and international participants and will also be broadcast live and archived on the company’s website for later listening.
Perimeter (OTCQX: PYNKF) unveiled Claire™, an OCT+AI imaging system for intraoperative breast cancer margin assessment, at ASBrS 2026 (April 29–May 3) with live demos at Booth #325.
Claire received FDA PMA in March 2026 as the first AI-enabled U.S. device for this use, offers 10x higher resolution than X-ray/ultrasound at a 2mm imaging depth, and was trained on a library of over 2 million breast OCT images; commercial launch is pending.
Perimeter Medical Imaging AI (OTCQX: PYNKF) will present an update at the 2026 Bloom Burton & Co. Healthcare Investor Conference on April 21, 2026 at 10:00 a.m. ET at the Metro Toronto Convention Centre.
The presentation will be broadcast live and later archived in the company's Investors section under "News/Events."
Perimeter Medical Imaging AI (OTCQX: PYNKF) reported preliminary unaudited Q4 and full-year 2025 results showing record revenue and improved operating performance. FY2025 revenue was approximately $2.3M (up 172% YoY); Q4-2025 revenue was approximately $711K (up 143% YoY). The company received FDA PMA approval for Claire in March 2026 and expects a U.S. commercial launch in Q2-2026. Operating expenses and cash used in operations both improved year-over-year; cash on hand was approximately $2.5M as of December 31, 2025.